Fairvalue-Calculator Fairvalue-Calculator
EN DE

Vistagen Therapeutics, Inc (VTGN) Fair Value & Analysis

Healthcare · US · Market cap $26.4M

Price$0.6648
Fair Value$0.4655
Upside-30.0%
Quality95/100
Evidence: Low Range $0.3491 – $0.5818

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Vistagen Therapeutics, Inc (VTGN) currently trades at $0.6648, while our model-based Fair Value estimate is $0.4655 — implying the stock looks roughly 30.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH2…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Vistagen Therapeutics, Inc (VTGN) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.4655 versus a price of $0.6648 — about −30% (overvalued). Model-based estimate, not financial advice.
What is the fair value of VTGN?
Our 21-model fair value for Vistagen Therapeutics, Inc is $0.4655 (as of Jun 25, 2026), built from audited fundamentals. The current price is $0.6648.
What is the quality score of VTGN?
Vistagen Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.